Peficitinib clinical trials
Also written ASP015K.
How each study uses peficitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
32 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 0
Astellas Pharma Inc (22) · Astellas Pharma Global Development, Inc. (7) · Astellas Pharma China, Inc. (2) · Janssen Research & Development, LLC (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses peficitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 32
- A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to MethotrexateCompletedPhase 2Astellas Pharma IncNCT01554696Written as peficitinib
- A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid ArthritisCompletedPhase 2Astellas Pharma Global Development, Inc.NCT01565655Written as peficitinib
- A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDsCompletedPhase 3Astellas Pharma IncNCT02308163Written as Peficitinib
- A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentCompletedPhase 3Astellas Pharma IncNCT02305849Written as Peficitinib
- A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015KCompletedPhase 3Astellas Pharma IncNCT01638013Written as Peficitinib
- A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe PsoriasisCompletedPhase 2Astellas Pharma IncNCT01096862Written as peficitinib
- A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyCompletedPhase 2Astellas Pharma Global Development, Inc.NCT01711814Written as peficitinib
- A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)CompletedPhase 3Astellas Pharma China, Inc.NCT03660059Written as Peficitinib
- A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis SubjectsCompletedPhase 2Astellas Pharma IncNCT01649999Written as peficitinib
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid ArthritisCompletedPhase 1Astellas Pharma IncNCT01754805Written as peficitinib
- A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsCompletedPhase 1Astellas Pharma China, Inc.NCT04143477Written as peficitinib
- Pharmacokinetics Study in Patients With Impaired Hepatic FunctionCompletedPhase 1Astellas Pharma IncNCT02586194Written as ASP015K
- Bioequivalence Evaluation of a New and Current Tablet of ASP015KCompletedPhase 1Astellas Pharma IncNCT02531191Written as peficitinib
- Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly VolunteersCompletedPhase 1Astellas Pharma IncNCT01225224Written as peficitinib
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminCompletedPhase 1Astellas Pharma IncNCT02760342Written as peficitinib
- Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal FunctionCompletedPhase 1Astellas Pharma IncNCT02603497Written as ASP015K
- A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedPhase 2Janssen Research & Development, LLCNCT01959282Written as JNJ-54781532 25 mg once daily
- A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015KCompletedPhase 1Astellas Pharma Global Development, Inc.NCT01686217Written as ASP015K ER
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy SubjectsCompletedPhase 1Astellas Pharma Global Development, Inc.NCT02141425Written as ASP015K
- A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult SubjectsCompletedPhase 1Astellas Pharma Global Development, Inc.NCT02111317Written as ASP015K
Codes
What other systems call peficitinib · ClinicalTrials.gg INT000465
- MeSH (NLM) C000608065peficitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) HPH1166CKXPEFICITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27088288peficitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170291PeficitinibOne source FDA
- DrugBank DB11708One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608065 | peficitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | HPH1166CKX | PEFICITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088288 | peficitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170291 | Peficitinib | One source FDA |
| DrugBank | DB11708 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.